RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities during the specified Class Period of the upcoming lead plaintiff deadline on August 11, 2025 [1] Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities between September 17, 2024, and May 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4] Group 2: Case Allegations - The lawsuit alleges that Rocket Pharmaceuticals made false and misleading statements regarding the effectiveness and safety of its product RP-A501, which was overstated [5] - Specific claims include that RP-A501 was less effective than represented, and changes to its clinical trial protocol increased the risk of Serious Adverse Events [5]